379

A COMPARISON OF PATIENTS' AND PHYSICIANS' ASSESSMENTS OF DISEASE ACTIVITY USING THE SWEDISH VERSION OF THE SYSTEMIC LUPUS ACTIVITY QUESTIONNAIRE

¹S Pettersson*, ²E Svengsson, ²J Gustafsson, ¹S Möller, ²I Gunnarsson, ³E Welin Henriksson.

¹Karolinska University Hospital, Rheumatology Unit- D201, Stockholm, Sweden; ²Karolinska Institutet, Rheumatology Unit- Department of Medicine- Solna, Stockholm, Sweden;

³Linköping University, Division of Nursing Science- Department of Medical and Health Sciences-, Linköping, Sweden

10.1136/lupus-2017-000215.379

Background and aims We compared patients' assessments of Systemic Lupus Erythematosus (SLE) disease activity by a Swedish version of the Systemic Lupus Activity Questionnaire

(SLAQ) questionnaire with physicians' assessments by Systemic Lupus Activity Measure (SLAM) and SLE Disease Activity Index (SLEDAI). Additionally, we explored the performance of the SLAQ in patients with short (<1 year) versus long (≥1 year) disease duration.

Methods Patients filled out SLAQ prior to physicians' assessments. Correlations between SLAQ-total, sub-scales (Symptom score, Flares, Patients global) and SLAM and SLEDAI as well as between the corresponding items in SLAQ and SLAM were evaluated using Spearman's ρ . Comparisons between patients with different disease durations were performed with Mann-Whitney U or Chi-square tests.

Results We included 203 patients (79% women, median age 45 (IQR 33–57) years, disease duration 5 (IQR 0–14) years)

Abstract 379 Table 1 Characteristics of the 203 participants with SLE (women 79%).

	Median	IQR	Minimum	Maximum
Age (years)	45	33-57	18	82
Disease duration (years)	5	0-14	0	58
Symptom score (0-24)	10	6-14	0	24
SLAQ ^a score (0-47)	12	6-18	0	40
Flare ^b (0-3)	1	0-2	0	2
PNRS ^c (0-10)	4	1-7	0	10
SLAM ^d	6	3-10	0	24
SLAM ^e lab	5	2-7	0	21
SLEDAI ^e	4	0-7	0	26
SLICC/ACR DI ^f	1	0-2	0	10

^a SLAQ = Systemic Lupus Activity Questionnaire
^b Flare: patient global assessment of severity of lupus flare, Missing=32
^c PNRS: patient numerical rating scale of global disease activity, Missing=11
^d SLAM = Systemic Lupus Activity Measure
^e SLEDAI = SLE Disease Activity Index, Missing =1
^f SLICC/ACR DI = Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index

(Table 1). Correlations between physicians' SLAM, without laboratory items (SLAM-nolab), and patients' assessments were: SLAQ total, $\rho=0.685$, Symptom score, $\rho=0.651$, Flares, $\rho=0.547$ and Patients global, $\rho=0.600$. Of symptom items fatigue ($\rho=0.640$), seizures ($\rho=0.635$) and headache ($\rho=0.604$) correlated best. Neurology/stroke syndrome, skin and lymphadenopathy correlated less well ($\rho < 0.24$). Patients' and physicians' assessments were notably more discordant for patients with short disease durations.

Conclusions We confirm that the SLAQ can be used to monitor disease activity. However, the discrepancy between patients' and physicians' assessments was greater for patients with short versus long disease duration. We encourage further use of the SLAQ, but would like to develop a shorter version which would be valuable in modern, partly web-based, clinical care.

380

COMPARISONS OF FATIGUE, ANXIETY AND DEPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC SCLEROSIS AND ANTI-NEUTROPHIL CYTOPLASMATIC ANTIBODY-ASSOCIATED VASCULITIS

^{1,2}S Pettersson*, ³A Nordin, ³E Svenungsson, ³I Gunnarsson. ¹Karolinska University Hospital, Rheumatology Unit- D201, Stockholm, Sweden; ²Karolinska Institutet, Division of Physiotherapy- Department of Neurobiology- Care Sciences and Society, Stockholm, Sweden; ³Karolinska Institutet- Karolinska University Hospital, Department of Medicine- Unit of Rheumatology- Karolinska University Hospital-, Stockholm, Sweden

10.1136/lupus-2017-000215.380

Background and aims To compare fatigue, anxiety and depression between systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic antibody associated vasculitis (AAV).

Methods Patients filled in self-assessments of fatigue (Multi Assessment of Fatigue Scale, MAF) and anxiety/depression

Abstract 380 Table 1 Comparison of fatigue between three cohorts^a of inflammatory disorder.

	SLE (n=417) Median (IQR)	SSc (n=212) Median (IQR)	AAV (n=227) Median (IQR)	p-value ^b		
				SLE vs SSc	SLE vs AAV	SSc vs AAV
Age (years)	47 (34-57)	60 (52-69)	62 (49-69)	<0.001	<0.001	0.296
Disease (years)	10 (2-20)	2 (0-8)	3 (0-8)	<0.001	<0.001	0.807
<i>Fatigue^c</i>						
Global ^c (1-50)	30.4 (21.4-38.9)	26.9 (18.5-35.1)	27.8 (18.7-33.7)	0.001	0.001	0.899
Degree ^c (1-10)	7 (5-9)	6 (4-8)	7 (4-8)	<0.001	0.002	0.429
Severity ^c (1-10)	6 (4-8)	6 (4-7)	6 (3-7)	0.001	0.002	0.803
Distress ^d (1-10)	6 (3-8)	5 (2-7)	5 (3-7)	0.007	0.005	0.956
Activities ^d (1-10)	3.6 (1.8-5.6)	3.4 (1.8-4.9)	3.0 (1.9-4.4)	0.084	0.010	0.358
Anxiety ^c (0-14)	6 (3-9)	5 (2-7.8)	5 (2-9)	0.013	0.007	0.767
Depression ^c (0-14)	4 (2-7)	4 (2-6.8)	4 (1-7)	0.596	0.191	0.453

a: SLE=systemic lupus erythematosus, SSc=systemic sclerosis, AAV= anti-neutrophil cytoplasmic antibody associated vasculitis

b: Mann-Whitney U

c: Fatigue components from Multi Assessment of Fatigue Scale

d: Hospital Anxiety and Depression Scale.